Grants for For profit organizations other than small businesses - Science and Technology

This program provides financial support to farms and agricultural businesses in Garrett County, Maryland, to enhance their marketing efforts and boost local agricultural economic activity.

The U.S. National Science Foundations Directorate for Technology, Innovation and Partnerships (TIP) is charged with accelerating use-inspiredand translationalresearch and development (R) to advance U.S. competitiveness in key technology focus areas. The Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (CFIRE) initiative will accelerate the adoption of cell-free systems, enable new applications of this technology and contribute to the growth of the U.S. bioeconomy. A nascent industry has formed around the ability to carry out biochemical processes, such as DNA transcription/translation, in cell-free in-vitro systems instead of in traditional cell-based in-vivo bio-reactors. This approach has a number of potential advantages, including rapid turn-around, distributed and highly retargetable manufacturing, high-fidelity instrumentation and control of the manufacturing environments without the constraints of biological growth and the interference caused by cell biomass and cell membranes during product purification. Furthermore, cell-free systems can produce products that are challenging to manufacture in cell-based cultures, such as those inherently toxic to cells or hydrocarbon products that are consumed by the cellular machinery. Despite these advantages, present-day cell-free manufacturing is significantly more expensive than cell-based methods and cell-free systems have a limited range of applications. CFIRE aims to: 1. Reduce the cost of cell-free systems; 2. Increase the range and capabilities of cell-free systems; and 3. Develop and demonstrate cost-effective use-inspired applications. CFIRE will address the key limitations of cell-free technology by identifying technical approaches that can enable ongoing cycles of improvement. The objective is to place cell-free technology on an exponential growth path in which reduced costs lead to increasing adoption which, in turn, generates the learning and investment required to further reduce costs. In order to keep the work focused and to stimulate increasing adoption, efforts funded through this initiative will focus on one or more specific use cases. CFIRE seeks significant breakthroughs that will accelerate the adoption of cell-free systems by: (a) Demonstrating the feasibility and advantages of cell-free systems through use-inspired applications with specific emphasis on applications beyond human therapeutics; (b) Creating infrastructure components, such as tools, protocols, kits, datasets, and characterization services that can readily be accessed by third parties; and (c) Investing in workforce components focused on the training of translational talent with the skills and passion to engage in use-driven cell-free applications. CFIRE will use the Ideas Lab process (see PAPPG Chapter II.F.6), starting with an intensive meeting that brings together multiple diverse perspectives. The primary objectives of this Ideas Lab workshop will be to: identify specific opportunities to significantly reduce the cost of cell-free systems; establish acceptable standards for the fidelity and reproducibility; expand the range of capabilities in order to facilitate broader adoption of the technology; and identify and prioritize use-driven applications beyond human therapeutics.

This funding opportunity supports events and projects that boost tourism in Union County, Ohio, targeting both nonprofit and for-profit organizations, as well as municipalities, to enhance the area's appeal and economic impact.

This funding opportunity supports independent researchers in studying the prevention, diagnosis, and treatment of diseases related to military toxic exposures, benefiting Service Members, Veterans, and their families.

The Spark Cleantech Accelerator (CTA) is a 12-week in-person program at the UT Research Park in Knoxville, Tennessee, designed to support early-stage cleantech businesses and drive the commercialization of their technologies. Created in partnership with Evergreen Climate Innovations, the program aims to foster innovation in Tennessee, the Midwest, and the Southeast. This initiative aligns with the broader mission of supporting sustainable technological advancements and economic development in the region by focusing on emerging cleantech enterprises. The program targets early-stage cleantech entrepreneurs and companies, particularly those with applications from Tennessee, the Midwest, and beyond. Eligible businesses are those demonstrating a positive impact on energy efficiency, renewable energy generation, greenhouse gas emissions reduction, carbon capture, increased recycling/upcycling, and a circular economy. The program prioritizes companies with strong market potential, defensible intellectual property (issued or pending patents), and technologies that can address the challenges of Spark partners such as utilities, local governments, and manufacturing companies. It also focuses on software or hardware technologies, including intelligent connected devices and advanced materials processes, at a Technology Readiness Level (TRL) of 2-6, and applicants open to establishing a permanent business location in Tennessee. The Spark CTA provides a comprehensive suite of services, including $15,000 stipends to offset travel/living costs and support business/technical milestones, prototyping services through the University of Tennessee’s Center for Materials Processing, and one-on-one mentorship from experts in various fields like business, market analysis, IP/patent strategy, product design, engineering, and manufacturing. It also facilitates crucial connections with customers, investors, strategic partners, suppliers, universities, and national laboratories, along with training workshops. The program emphasizes partnership opportunities with key organizations such as the Tennessee Valley Authority, Oak Ridge National Lab, and the City of Knoxville. Expected outcomes include the successful commercialization of new cleantech innovations, the growth of early-stage cleantech businesses, and the creation of a vibrant cleantech ecosystem in Tennessee and surrounding regions. Measurable results would encompass the number of businesses supported, the development and deployment of new technologies, the securing of investments, and the establishment of new partnerships. The program's strategic priority is to accelerate the development and market entry of technologies that contribute to environmental sustainability and economic prosperity, operating on a theory of change that by providing targeted support, resources, and connections, early-stage cleantech companies can overcome barriers to commercialization and achieve significant impact.

The key aspects of this award are: Impact: The SRA is intended to support research designed to have a major impact on the health and well-being of melanoma survivors, their families, and/or caregivers. Impactful research will accelerate the movement of promising ideas into clinical applications or other real-world applications and advance the field of melanoma-specific quality of life and survivorship. Study Design: Applications should clearly articulate and justify the chosen study design. Studies proposing retrospective analyses or prospective enrollment should clearly describe the architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses) and the study population(s). The study population(s) should be representative of the people who are anticipated to benefit from the research. If applicable, questionnaires should be described in sufficient detail to justify interpretation of potential results. Melanoma Consumer Collaboration: For the purposes of the SRA, a melanoma consumer is defined as a melanoma survivor, family member, and/or caregiver who can provide lived experience expertise to the research project team. Applicants to the SRA are required to establish a collaborative research approach with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended melanoma community(ies). The research team must include at least one melanoma consumer or a melanoma-community supporting organization who will be integral to the planning, execution, and implementation of the proposed research. The role of the melanoma consumer collaborator(s) should include providing objective input on the research question being addressed; the study design, execution, and evaluation; and the potential impact of the research outcomes on the health and well-being of melanoma survivors, their families, and/or their caregivers. The melanoma consumer collaborator(s) should be active participants and integrated into the research team; their participation should not be limited only to passive activities (e.g., attending seminars or quarterly team meetings). Additional information and resources for establishing a collaborative research approach with the melanoma consumer community is provided below.Other Important Considerations:Collaborative Research Approaches: Collaborative research approaches create partnerships between scientific researchers and, for the purposes of the SRA, melanoma consumers to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and melanoma consumers collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of the melanoma consumers within the research team. Research results are jointly interpreted, disseminated, and fed back to affected communities and in some instances may be translated into interventions or policy.Collaborative relationships with the melanoma consumer community may be established through integrating melanoma consumers and/or melanoma-community supporting organizations into research teams as co-researchers, advisors, and/or consultants. Examples for implementing collaborative research approaches are listed below, but each research team may pursue other options as appropriate for the proposed research: The research team includes at least one melanoma consumer who will provide advice and consultation throughout the planning and implementation of the research project. The consumer(s) should be able to speak to the needs of the melanoma consumer community, not just speak to their own personal experiences. The research team establishes partnerships with at least one community-supporting organization that provides advice and consultation throughout the planning and implementation of the research project. Community-supporting organizations may include advocacy groups or other formal organizational stakeholders that can speak to the needs of the melanoma consumer community. The research team assembles a melanoma consumer community advisory board. The advisory board may include melanoma consumers, a coalition of community-supporting organizations, or any combination thereof that provides advice and consultation throughout the planning and implementation of the overall program and/or individual research projects.

The Arkansas Department of Environmental Quality runs an annual Electronic Waste Grants. This initiative aims to address electronic waste through projects focused on collection, transportation, processing, recycling, demanufacturing, and innovative approaches to disposal. Eligible projects are evaluated based on the sustainability and impact of their e-waste recovery efforts, including the minimization of e-waste volumes, job creation in Arkansas, and the effectiveness of investment in the projects. Eligible applicants include a wide range of entities within Arkansas, such as private industries, educational institutions, governmental bodies, non-profits, and regional solid waste management boards. This program operates on a reimbursement basis. Grant renewed every year. Grant Annual opening/closing deadline: January 1st to June 1st

This award is to support community development and resilience with geospatial data and digital technology by engaging university-aged youth. The activities anticipated as part of this award will add valuable, free and openly accessible data to digital ecosystems of lower and middle income countries, which in turn can be used by USAID programs and humanitarian assistance activities. The award will specifically focus on youth training, geospatial data collection, and analysis to help communities address local development challenges. Activities will also engage marginalized populations to ensure representation of the diversity of partner country populations. USAID anticipates awarding one to three grants and/or cooperative agreements under this Addendum. Issuance of this Addendum does not constitute an award or commitment on the part of the U.S. Government to make an award, nor does it commit the U.S. Government to pay for costs incurred in the preparation and submission of a Concept Note or Application(s). The actual number of assistance awards is subject to the availability of funds, as well as the viability of eventual full Applications received.

This grant seeks innovative proposals from a wide range of organizations, including universities and small businesses, to develop advanced technologies that enhance national defense capabilities.

This grant provides funding to early-career researchers focused on melanoma to support their independent research and professional development while fostering collaboration within a network of experts.

This grant provides funding for research aimed at developing new therapies for amyotrophic lateral sclerosis (ALS), specifically targeting projects that have already shown promise in preclinical studies and emphasize the use of biomarkers for therapeutic development.

This funding opportunity provides financial support to nonprofit organizations and healthcare providers in New York to address racial disparities in maternal health for Black New Yorkers and other communities of color through innovative primary and preventive care solutions.

This funding opportunity supports various mentoring and intervention programs aimed at reducing violence and fostering positive relationships among youth and families in the community.

The MBRP TTDA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical application in resource-limited settings, particularly within the pre-hospital, or early, acute phase of care environments. Applications must address one or more of the critical gaps included in the FY24 MBRP TTDA Focus Areas. Products under development must address the needs of military Service Members, Veterans, their beneficiaries, and the American public.The product(s) to be developed may be a tangible item such as a medical device or pharmacologic agent (including, but not limited to, drugs or biologics). Knowledge products may be considered, provided that the knowledge is applicable to a technology or therapeutic under development. (A knowledge product is a non-materiel product that addresses an identified need in one or more of the FY24 MBRP TTDA Focus Areas. A knowledge product is based on current evidence, aims to transition clinical practice standards, training, or tools into clinical practice, or supports materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)At the time of pre-application submission the proposed product must have achieved a minimum technology readiness level (TRL) or knowledge readiness level (KRL) of 3 (Appendix II).Proof-of-concept AND a prototype/preliminary version of the proposed product demonstrating its potential utility must be established at the time of pre-application submission. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.This award mechanism is intended to facilitate progression of research that is supported by significant preliminary data but has not yet advanced to the level of clinical use. Examples of the types of research that may be supported include, but are not limited to: Testing new therapeutic or technologic modalities (e.g., agents, delivery systems, chemical modification of lead compounds, device testing and/or validation) using established or validated preclinical systems Designing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or technologies for use in advanced preclinical studies Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity studies Investigational New Drug- or Investigational Device Exemption-enabling studiesClinical trials and clinical research studies ARE NOT PERMITTED under this award mechanism. Projects involving limited use of commercially available human cells or anatomical specimens are permitted, provided that the use of such specimens is necessary for device or product development. Applicants interested in proposing clinical research should consider submitting to the FY24 MBRP Patient-Centered Research Award mechanism (HT942524MBRPPCRA).A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Impact: The overall impact of the proposed research is a key component of this award mechanism. High-impact research will, if successful, lead to the development and translation of therapeutic or technologic advances for clinical application in the care of burn-injured casualties, such as detection, diagnosis, treatment, or burn complication prevention.Relevance to Military Health: Relevance to the health care needs of burn-injured military Service Members is a key feature of this award.Use of DOD or Department of Veterans Affairs (VA) Resources: Applications involving multidisciplinary collaborations among academia, industry, the military Services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix IV.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.The CDMRP expects to allot approximately $4.4M to fund approximately two MBRP Technology/Therapeutic Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.The funding instrument for awards made under the program announcement will be assistance agreements, contracts, or Other Transactions. The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. The USAMRDC will also consider the use of Other Transactions (OTs) as a vehicle for award, in accordance with the conditions in 10 USC 4021 and 10 USC 4022.An assistance agreement can take the form of a grant or cooperative agreement. The level of government involvement during the projects period of performance is the key factor in determining whether to award a grant or cooperative agreement. If no substantial government involvement is anticipated, a grant will be made (31 USC 6304). Conversely, if substantial government involvement is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that members of the U.S. government will assist, guide, coordinate, or participate in project activities.A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government.An Other Transaction will also be considered as a vehicle for award under this BAA, in accordance with 10 USC 4021 and 10 USC 4022. The OT authorities were created to give DOD the flexibility necessary to adopt and incorporate business practices that reflect commercial industry standards and best practices into its award instruments. When leveraged appropriately, OTs provide the government with access to state-of-the-art technology solutions from traditional and non-traditional defense contractors (NDCs), through a multitude of potential teaming arrangements tailored to the particular project and the needs of the participants. OTs can help to foster new relationships and practices involving traditional and NDCs, especially those that may not be interested in entering into FAR-based contracts with the government; broaden the industrial base available to government; support dual-use projects; encourage flexible, quicker, and cheaper project design and execution; leverage commercial industry investment in technology development and partner with industry to ensure DOD requirements are incorporated into future technologies and products; and collaborate in innovative arrangements. OTs are not FAR-based procurement contracts, grants, cooperative agreements, or cooperative research and development agreements.The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY24 MBRP Technology/Therapeutic Development Award should not exceed $2.2M. Refer to Section II.D.6, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025. For additional information refer to Section II.F.1, Federal Award Notices.

The County History Partnership Program (CHPP), established in 2015 by the New Jersey Historical Commission (NJHC), aims to decentralize the administration of local re-granting programs across all 21 New Jersey counties. This initiative directly aligns with the mission to support local history organizations that serve the public, fostering a broader engagement with the state's historical heritage. The program is administered by the Somerset County Cultural & Heritage Commission, which functions as the donor, extending the NJHC's strategic goal of strengthening local historical infrastructure. The primary beneficiaries of this grant are historical societies, organizations, nonprofits, and municipalities responsible for historic structures or archaeological sites. Eligible applicants must be Somerset County-based. The program's impact goals revolve around increasing public access to New Jersey history, expanding knowledge of the state's past, and improving the management capabilities of local history organizations. This approach is intended to create a more robust and accessible local history ecosystem within Somerset County. The grant prioritizes organizations that provide programs or services that achieve these goals. Specifically, applicants must demonstrate a commitment to enhancing public access to history or expanding historical knowledge. Another key focus is on improving the operational and managerial effectiveness of local history organizations, thereby ensuring their long-term sustainability and impact. The foundation's theory of change appears to be that by empowering local organizations with financial support and clear objectives, they can more effectively serve the public and preserve historical assets. Expected outcomes include a more engaged public with New Jersey history, a greater depth of historical knowledge disseminated, and more efficiently run local history organizations. Measurable results would likely include increased participation in historical programs, documented improvements in organizational management, and successful preservation efforts of historic sites. Organizations are also required to have provided public history programs and/or services in Somerset County for the benefit of the general public for at least two years prior to application, and must provide proof of stability and fiscal responsibility, ensuring the grant's investment is directed towards established and accountable entities.

This funding opportunity provides financial support for faculty and students at under-resourced academic institutions to collaborate with NASA on research projects, fostering mentorship and skill development in STEM fields.

This initiative provides up to $10 million in prizes to innovators developing advanced LED lighting solutions that improve energy efficiency, quality, and accessibility for commercial use.

This funding opportunity supports small U.S.-based businesses in developing and scaling innovative therapies using extracellular vesicles for regenerative medicine applications, such as tissue and organ repair.

The District of Columbia Child and Family Services Agency (CFSA) invites applications for funding to support community-based organizations in implementing place-based initiatives. The overarching goal is to improve the well-being and stability of families through community-driven efforts. This aligns with a mission to empower local communities by providing resources and services that directly address their specific needs and strengths, fostering self-sufficiency and improved family outcomes. The grant program aims to establish and support Family Success Centers, which will serve as accessible hubs for neighbors to utilize computers, access various resources and services, and participate in classes and trainings. Each center is designed to be unique, reflecting the specific strengths and goals of its community, ensuring that the support provided is relevant and impactful. This model focuses on localized solutions, recognizing that effective family support is best achieved when tailored to the community it serves. Target beneficiaries for these initiatives are families within the District of Columbia, with a particular focus on those who can benefit from enhanced access to resources and services that improve well-being and stability. The impact goals include fostering stronger, more resilient families and communities by addressing multiple aspects of family life. This approach seeks to create a network of support that is easily accessible and responsive to the evolving needs of residents. The program prioritizes non-profit, community-based organizations that can demonstrate their ability to meet identified needs and commit to implementing program measures over the grant period. Eligible organizations include non-profit, private, public, and faith-based entities. Partnerships between organizations are encouraged to facilitate comprehensive service delivery. Expected outcomes include increased access to vital resources, improved family well-being, enhanced community stability, and the development of sustainable, community-led initiatives. Measurable results will likely include metrics related to service utilization, program participation, and indicators of family and community stability and well-being. Funding information indicates that eligible organizations can receive up to $325,000 in the 12-month base year, with the potential for an additional $325,000 per year for up to four option years, for a maximum grant duration of five years. This sustained funding is intended to support the long-term implementation and impact of these place-based family support initiatives. The strategic priority is to invest in local organizations that are deeply embedded within the communities they serve, thereby leveraging existing community strengths and relationships to achieve lasting positive change.

The DoD Breast Cancer, Transformative Breast Cancer Consortium Development Award is a funding opportunity aimed at providing resources to establish a multi-institutional research team, including scientists, clinicians, and breast cancer advocates, to conduct preliminary research and develop a consortium framework for future application to a full Transformative Breast Cancer Consortium Award, with a focus on innovative research for early diagnosis and effective treatment of breast cancer relevant to active-duty Service Members, Veterans, military beneficiaries, and the American public.